Skip to content
          • Log In
      Drug Discovery World (DDW)Drug Discovery World (DDW)
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
          Drug Discovery World (DDW) Menu   ≡ ╳
          • Home
          • News
          • Exclusive Content
            • Features
            • Opinion
            • Market Reports
            • Trends & Analysis
            • Start-up Zone
          • DDW eBooks & eReports
          • Cancer Research
          • Business
          • Regulatory
          • Events
          • Webinars
          • Resources
          • Archive
            • –
              • 2000 Archive
              • 2001 Archive
              • 2002 Archive
              • 2003 Archive
              • 2004 Archive
              • 2005 Archive
              • 2006 Archive
            • –
              • 2007 Archive
              • 2008 Archive
              • 2009 Archive
              • 2010 Archive
              • 2011 Archive
              • 2012 Archive
              • 2013 Archive
            • –
              • 2014 Archive
              • 2015 Archive
              • 2016 Archive
              • 2017 Archive
              • 2018 Archive
              • 2019 Archive
          • Multimedia
            • Videos
            • Podcasts

          Sidebar Banner 6

          Sidebar Banner 7

          Sidebar Banner 8

          Sidebar Banner 12

          Sidebar Banner 18

          Sidebar Banner 19

          Sidebar Banner 20

          Sidebar Banner 21

        Endogena Therapeutics

        Ophthalmologist looks at retinal scan

        Retinitis pigmentosa drug proved safe in Phase I/IIa study

        11 April 2023

        Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. Given the positive safety and tolerability profile, the study will now enrol patients into the expansion cohort, using the highest dose evaluated in the study to explore the potential […]

        ""

        FDA Fast Track Designation for retinitis pigmentosa treatment

        8 February 2023

        The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development programme.   Fast Track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions.   EA-2353 takes a novel, small-molecule approach and selectively […]

        Sidebar Banner 1

        Sidebar Banner 2

        Sidebar Banner 3

        Sidebar Banner 4

        Sidebar Banner 9

        Sidebar Banner 10

        Sidebar Banner 11

        Sidebar Banner 13

        Sidebar Banner 14

        Sidebar Banner 15

        Sidebar Banner 16

        Sidebar Banner 17

          • Contact Us
          • About Us
          • Subscribe FREE
          • Media Info
          • Log In
          • Terms and Conditions
          • Privacy Policy
          • Cookie Policy

        Follow our social accounts

             

        Copyright 2023 © Drug Discovery World (DDW). All Rights Reserved

        Designed & Developed with ❤ for digital by Inbound FinTech

        • Home
        • News
        • Exclusive Content
          • Features
          • Market Reports
          • Opinion
          • Trends & Analysis
          • Start-up Zone
        • DDW eBooks & eReports
        • Cancer Research
        • Business
        • Regulatory
        • Events
        • Webinars
        • Resources
        • Archive
        • Multimedia
          • Podcasts
          • Videos
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
            • Log In